These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 26114946

  • 1. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
    Provan SA, Berg IJ, Hammer HB, Mathiessen A, Kvien TK, Semb AG.
    PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 3. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    JAMA Intern Med; 2017 Nov 01; 177(11):1605-1612. PubMed ID: 28975211
    [Abstract] [Full Text] [Related]

  • 4. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
    Grøn KL, Glintborg B, Nørgaard M, Mehnert F, Østergaard M, Dreyer L, Krogh NS, Hetland ML.
    Rheumatology (Oxford); 2020 Aug 01; 59(8):1949-1956. PubMed ID: 31764977
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Int J Rheum Dis; 2016 Nov 01; 19(11):1103-1111. PubMed ID: 26692536
    [Abstract] [Full Text] [Related]

  • 6. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
    Gülfe A, Wallman JK, Kristensen LE.
    Arthritis Res Ther; 2016 Feb 19; 18():51. PubMed ID: 26892115
    [Abstract] [Full Text] [Related]

  • 7. Factors associated with change in arterial stiffness in patients with rheumatoid arthritis: the JointHeart study.
    Linde A, Gerdts E, Fevang BT, Eilertsen RK, Kringeland E, Alsing CL, Midtbø H.
    Blood Press; 2024 May 09; 33(1):2353167. PubMed ID: 38824646
    [Abstract] [Full Text] [Related]

  • 8. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
    Grøn KL, Arkema EV, Glintborg B, Mehnert F, Østergaard M, Dreyer L, Nørgaard M, Krogh NS, Askling J, Hetland ML, ARTIS Study Group.
    Ann Rheum Dis; 2019 Mar 09; 78(3):320-327. PubMed ID: 30612115
    [Abstract] [Full Text] [Related]

  • 9. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR.
    Arthritis Rheumatol; 2016 Jan 09; 68(1):56-66. PubMed ID: 26315675
    [Abstract] [Full Text] [Related]

  • 10. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL.
    Arthritis Res Ther; 2015 Nov 11; 17():319. PubMed ID: 26555431
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
    Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, Hanami K, Saito K, Tanaka Y.
    Ann Rheum Dis; 2016 Jul 11; 75(7):1321-7. PubMed ID: 26245754
    [Abstract] [Full Text] [Related]

  • 12. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
    Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH.
    Ann Rheum Dis; 2014 May 11; 73(5):909-12. PubMed ID: 24385201
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, Puolakka K, Nordström D, Blom M.
    PLoS One; 2019 May 11; 14(7):e0220142. PubMed ID: 31339961
    [Abstract] [Full Text] [Related]

  • 14. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X, French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.
    BMJ; 2019 Jan 24; 364():l67. PubMed ID: 30679233
    [Abstract] [Full Text] [Related]

  • 15. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment.
    Mathieu S, Pereira B, Dubost JJ, Lusson JR, Soubrier M.
    Rheumatology (Oxford); 2012 Jun 24; 51(6):1107-11. PubMed ID: 22328565
    [Abstract] [Full Text] [Related]

  • 16. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
    Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A, Listing J.
    Ann Rheum Dis; 2017 Mar 24; 76(3):504-510. PubMed ID: 27405509
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept.
    Hirota T, Suzuki T, Ogishima H, Hagiwara S, Ebe H, Takahashi H, Yokosawa M, Umeda N, Kondo Y, Tsuboi H, Matsumoto I, Sumida T.
    Mod Rheumatol; 2016 Mar 24; 26(1):29-35. PubMed ID: 26140463
    [Abstract] [Full Text] [Related]

  • 18. Generalized estimating equation model to compare drug effects on synovitis of the dominant wrist in severe rheumatoid arthritis between tocilizumab versus adalimumab versus abatacept using high-resolution ultrasound.
    Chen YC, Chiu WC, Su FM, Chen JF.
    Int J Rheum Dis; 2018 Sep 24; 21(9):1695-1700. PubMed ID: 29024421
    [Abstract] [Full Text] [Related]

  • 19. Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis.
    Schäfer M, Meißner Y, Kekow J, Berger S, Remstedt S, Manger B, Listing J, Strangfeld A, Zink A.
    Rheumatology (Oxford); 2020 Aug 01; 59(8):1916-1926. PubMed ID: 31745566
    [Abstract] [Full Text] [Related]

  • 20. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial.
    Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N.
    J Rheumatol; 2011 Oct 01; 38(10):2169-71. PubMed ID: 21807781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.